Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA

Posted on by

STOCKHOLM, Nov. 13, 2023 /PRNewswire/ — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that clinical data from the ongoing phase 1b/2a study of in fostroxacitabine…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.